FREMEDOL FLU

FREMEDOL FLU

Home / Products / FREMEDOL FLU
Home / Products / FREMEDOL FLU

FREMEDOL FLU

Active ingredients:

Paracetamol 325 mg, dextromethorphan hydrobromide 10 mg, guaifenesin 200 mg, phenylephrine hydrochloride 5 mg.

Dosage form: Film-coated tablet.

Packaging:

Box of 1 aluminum pouch containing 2 blisters, 10 tablets per blister.

Box of 2 aluminum pouches, each pouch containing 5 blisters, 10 tablets per blister.

Box of 2 aluminum pouches, each pouch containing 6 blisters, 10 tablets per blister.

Expiry date: 36 months.

Posology

Adults and children 12 years and over: 2 tablets every 4 hours. Do not take more than 10 tablets in 24 hours.

Children under 12 years: Ask a doctor.

Administration

Oral use.

INDICATIONS

  • For the temporary relief of the symptoms of colds and flu: minor aches and pains, headache, sore throat, nasal congestion, cough.
  • Helps loosen phlegm (mucus) and thin bronchial secretions to make coughs more productive.
  • Reduces fever.

CONTRAINDICATIONS

Paracetamol

Hypersensitivity to paracetamol or any of the excipients.

Severe liver failure.

Dextromethorphan hydrobromide

Hypersensitivity to dextromethorphan or any of the excipients.

Patients taking monoamine oxidase inhibitors (MAOIs) may experience severe reactions including high fever, dizziness, hypertension, cerebral hemorrhage, and potentially fatal outcomes.

Children under 2 years of age.

Guaifenesin

Hypersensitivity to guaifenesin or any of the excipients.

Children under 4 years of age.

Phenylephrine hydrochloride

Hypersensitivity to the phenylephrine hydrochloride, pseudoephedrine (including cross-sensitivity), or to any of the excipients.

Severe cardiovascular disease, including myocardial infarction and coronary artery disease.

Severe hypertension, atrioventricular (AV) block, advanced arteriosclerosis, and ventricular tachycardia.

Severe hyperthyroidism or angle-closure glaucoma.

Oral administration is contraindicated in patients receiving MAOIs, or who have discontinued MAOIs treatment within the past 14 days, due to the risk of severe adverse reactions.

During the first trimester of pregnancy.